Shareholders Alert: Investigation Into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky to Protect Your Rights
New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws. What Happened? On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for...
2026-02-02 12:26 AM EST
Did You Suffer Losses in First Western Financial, Inc. (MYFW)? Contact Levi & Korsinsky About Securities Fraud Claims
New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into First Western Financial, Inc. ("First Western Financial, Inc.") (NASDAQ: MYFW) concerning potential violations of the federal securities laws. First Western reported its financial results for the fourth quarter of 2025 on January 22, 2026. Among other items, the Company reported quarterly earnings of $0.34 per share, missing analyst expectations. Following...
2026-02-02 12:21 AM EST
Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today
New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential violations of the federal securities laws. On January 28, 2026, Regenxbio disclosed via Form 8-K that the FDA placed clinical holds on its RGX-111 and RGX-121 programs following the identification of a tumor in a trial participant. The disclosure prompted a 30-35% decline in the company's...
2026-02-02 12:18 AM EST
Did You Suffer Losses in Bgin Blockchain Limited (BGIN)? Contact Levi & Korsinsky About Securities Fraud Claims
New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Bgin Blockchain Limited ("Bgin Blockchain Limited") (NASDAQ: BGIN) concerning potential violations of the federal securities laws. Bgin released unaudited financial results on November 14, 2025, for the six months ended June 30, 2025, revealing that total revenue had declined roughly $96 million from the previous year, operating expenses increased 582.8%,...
2026-02-02 12:16 AM EST
Levi & Korsinsky Investigates Possible Securities Fraud by First Western Financial, Inc. (MYFW)
New York, New York--(Newsfile Corp. - January 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into First Western Financial, Inc. ("First Western Financial, Inc.") (NASDAQ: MYFW) concerning potential violations of the federal securities laws. First Western reported its financial results for the fourth quarter of 2025 on January 22, 2026. Among other items, the Company reported quarterly earnings of $0.34 per share, missing analyst expectations. Following...
2026-01-30 2:00 PM EST
RGNX ALERT: Levi & Korsinsky Investigates REGENXBIO Inc. for Possible Securities Fraud Violations
New York, New York--(Newsfile Corp. - January 29, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential violations of the federal securities laws. On January 28, 2026, Regenxbio disclosed via Form 8-K that the FDA placed clinical holds on its RGX-111 and RGX-121 programs following the identification of a tumor in a trial participant. The disclosure prompted a 30-35% decline in the company's...
2026-01-29 11:41 AM EST
HDB ALERT: Levi & Korsinsky Investigates HDFC Bank Limited on Behalf of Shareholders Who Lost Money
New York, New York--(Newsfile Corp. - January 29, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into HDFC Bank Limited ("HDFC Bank Limited") (NYSE: HDB) concerning potential violations of the federal securities laws. During the post-merger integration period, HDFC Bank reported healthy credit expansion as the combined entity leveraged its enhanced distribution network and customer base. However, deposit growth did not keep pace with this loan book...
2026-01-29 11:16 AM EST
Investigation Underway: Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky Over Securities Law Violations
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws. What Happened? On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for...
2026-01-26 12:32 AM EST
Ongoing Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Protect Your Rights - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ: RARE) concerning potential violations of the federal securities laws. Ultragenyx reported the study results on December 29, 2025. Both studies failed to achieve their primary endpoint of a reduction in annualized clinical fracture rate against placebo in the Orbit study and against...
2026-01-26 12:30 AM EST
Ongoing Mereo BioPharma Group plc (MREO) Investigation: Protect Your Rights - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Mereo BioPharma Group plc ("Mereo BioPharma Group plc") (NASDAQ: MREO) concerning potential violations of the federal securities laws. On December 29, 2025, before the market opened, Mereo announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). The company reported that neither study failed to...
2026-01-26 12:27 AM EST
Fraud Investigation: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws. What Happened? On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension...
2026-01-26 12:24 AM EST
Levi & Korsinsky Launches Fraud Investigation on Behalf of Bgin Blockchain Limited (BGIN) Shareholders
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Bgin Blockchain Limited ("Bgin Blockchain Limited") (NASDAQ: BGIN) concerning potential violations of the federal securities laws. Bgin released unaudited financial results on November 14, 2025, for the six months ended June 30, 2025, revealing that total revenue had declined roughly $96 million from the previous year, operating expenses increased 582.8%,...
2026-01-26 12:21 AM EST
ATTENTION BGIN Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Bgin Blockchain Limited ("Bgin Blockchain Limited") (NASDAQ: BGIN) concerning potential violations of the federal securities laws. Bgin released unaudited financial results on November 14, 2025, for the six months ended June 30, 2025, revealing that total revenue had declined roughly $96 million from the previous year, operating expenses increased 582.8%,...
2026-01-21 2:44 PM EST
INO Investor Notice: Levi & Korsinsky Investigates Inovio Pharmaceuticals, Inc. for Securities Law Violations
New York, New York--(Newsfile Corp. - January 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Inovio Pharmaceuticals, Inc. ("Inovio Pharmaceuticals, Inc.") (NASDAQ: INO) concerning potential violations of the federal securities laws. The U.S. Food and Drug Administration ("FDA") announced on December 29, 2025, it had accepted Inovio's Biologics License Application ("BLA") for INO-3107, a treatment for recurrent respiratory papillomatosis, on a...
2026-01-21 2:42 PM EST
Shareholders Alert: Investigation Into Wealthfront Corporation (WLTH) - Contact Levi & Korsinsky to Protect Your Rights
New York, New York--(Newsfile Corp. - January 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Wealthfront Corporation ("Wealthfront Corporation") (NASDAQ: WLTH) concerning potential violations of the federal securities laws. On January 13, 2026, Barron's reported that shares of Wealthpoint "dropped 14% Tuesday morning after the wealth management company reported quarterly earnings and provided data on Monday afternoon that showed some softening in...
2026-01-21 1:10 PM EST
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Instil Bio, Inc. ("Instil Bio, Inc.") (NASDAQ: TIL) concerning potential violations of the federal securities laws. Instil issued a press release on January 6, 2026, announcing that Axion Bio, Inc. ("Axion"), an Instil subsidiary, "has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ....
2026-01-20 3:03 PM EST
Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT)
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Rezolute, Inc. (NASDAQ: RZLT) ("Rezolute, Inc.") concerning potential violations of the federal securities laws. On December 11, 2025, before the market opened, Rezolute announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism. The company reported that the study did not meet its primary...
2026-01-19 12:47 AM EST
Ongoing Securities Investigation into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive Therapeutics, Inc.") concerning potential violations of the federal securities laws. What Happened? On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for...
2026-01-19 12:43 AM EST
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin Therapeutics Inc.") concerning potential violations of the federal securities laws. Galectin issued a press release on December 19, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted...
2026-01-19 12:32 AM EST
Levi & Korsinsky Investigates Possible Securities Fraud by Corcept Therapeutics Incorporated (CORT)
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated (NASDAQ: CORT) ("Corcept Therapeutics Incorporated") concerning potential violations of the federal securities laws. What Happened? On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension...
2026-01-19 12:27 AM EST